• +1-646-491-9876
    • +91-20-67278686

    Search

    Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017

    Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689437
    • Category Healthcare
    • No. of Pages 89
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

    Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying your bladder, constipation and backache or leg pains.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
    - The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Uterine Leiomyoma (Uterine Fibroids) - Overview
    Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
    AbbVie Inc
    Addex Therapeutics Ltd
    Bayer AG
    BioSpecifics Technologies Corp
    Dongkook Pharmaceutical Co Ltd
    Kissei Pharmaceutical Co Ltd
    Laboratoire HRA Pharma
    Ogeda SA
    Repros Therapeutics Inc
    Takeda Pharmaceutical Company Ltd
    Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
    collagenase clostridium histolyticum - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Endometriosis and Uterine Fibroids - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elagolix sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EVE-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fezolinetant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KLH-2109 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    relugolix - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    telapristone acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    triptorelin biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ulipristal acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vilaprisan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPE-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VPEA-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
    Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
    Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
    Featured News & Press Releases
    Jan 30, 2017: FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex in the Treatment of Uterine Fibroids
    Jan 25, 2017: Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
    Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
    Dec 12, 2016: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Symptomatic Uterine Fibroids
    Nov 21, 2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment
    Nov 14, 2016: Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex Delivered Orally and Vaginally for the Treatment of Uterine Fibroids
    Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City
    Oct 13, 2016: Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM
    Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
    May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
    May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
    May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
    Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
    Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
    Dec 21, 2015: Repros Updates Proellex Program
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2017
    Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Addex Therapeutics Ltd
    Bayer AG
    BioSpecifics Technologies Corp
    Dongkook Pharmaceutical Co Ltd
    Kissei Pharmaceutical Co Ltd
    Laboratoire HRA Pharma
    Ogeda SA
    Repros Therapeutics Inc
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//uterine-leiomyoma-uterine-fibroids-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//uterine-leiomyoma-uterine-fibroids-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//uterine-leiomyoma-uterine-fibroids-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments